Cancer Research Donn Young  Protein Translation and Cancer
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Houghtaling, S.
Right arrow Articles by Grompe, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Houghtaling, S.
Right arrow Articles by Grompe, M.
[Cancer Research 65, 85-91, January 1, 2005]
© 2005 American Association for Cancer Research


Molecular Biology, Pathobiology and Genetics

Heterozygosity for p53 (Trp53+/–) Accelerates Epithelial Tumor Formation in Fanconi Anemia Complementation Group D2 (Fancd2) Knockout Mice

Scott Houghtaling1, Laura Granville2, Yassmine Akkari1, Yumi Torimaru1, Susan Olson1, Milton Finegold2 and Markus Grompe1

1 Department of Molecular and Medical Genetics, Oregon Health & Science University, Portland, Oregon and 2 Department of Pathology, Texas Children's Hospital, Baylor College of Medicine, Houston, Texas

Requests for reprints: Scott Houghtaling, Department of Molecular and Medical Genetics, Oregon Health & Science University, 3181 Southwest Sam Jackson Park Road, Mail Code L103, Portland, OR 97239. Phone: 503-494-6206. E-mail: houghtal{at}ohsu.edu

Fanconi anemia (FA) is an autosomal recessive disease characterized by progressive bone marrow failure and an increased susceptibility to cancer. FA is genetically heterogeneous, consisting of at least 11 complementation groups, FA-A through L, including FA-D1 (BRCA2) and D2. We have previously reported an increased incidence of epithelial tumors in Fancd2 knockout mice. To further investigate the role of the FA pathway in tumor prevention, Fancd2 mutant mice were crossed to mice with a null mutation in the tumor suppressor gene, Trp53. The tumor spectrum in Fancd2–/–/Trp53+/– mice included sarcomas expected in Trp53 heterozygotes, as well as mammary and lung adenocarcinomas that occur rarely in Trp53 heterozygotes. These tumors occurred earlier than in Fancd2–/– control mice. Therefore, the Fancd2–/–/Trp53+/– mice represent an improved model for the study of adenocarcinoma in FA. In addition, it was found that Fancd2–/– mouse embryonic fibroblasts but not Fancd2–/–/Trp53–/– mouse embryonic fibroblasts arrest following DNA damage. Therefore, Trp53 is required for the S phase checkpoint activation observed in Fancd2 mutant cells. Fancd2–/–/Trp53–/– cells showed an increase in aneuploidy and had multiple gross chromosomal rearrangements.

Key Words: Fanconi anemia • Fancd2 • Trp53 • Mammary Adenocarcinoma




This article has been cited by other articles:


Home page
Hum Mol GenetHome page
S. T. Bakker, H. J. van de Vrugt, M. A. Rooimans, A. B. Oostra, J. Steltenpool, E. Delzenne-Goette, A. van der Wal, M. van der Valk, H. Joenje, H. te Riele, et al.
Fancm-deficient mice reveal unique features of Fanconi anemia complementation group M
Hum. Mol. Genet., September 15, 2009; 18(18): 3484 - 3495.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
R. Rani, J. Li, and Q. Pang
Differential p53 Engagement in Response to Oxidative and Oncogenic Stresses in Fanconi Anemia Mice
Cancer Res., December 1, 2008; 68(23): 9693 - 9702.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
Q.-S. Zhang, L. Eaton, E. R. Snyder, S. Houghtaling, J. B. Mitchell, M. Finegold, C. Van Waes, and M. Grompe
Tempol Protects against Oxidative Damage and Delays Epithelial Tumor Onset in Fanconi Anemia Mice
Cancer Res., March 1, 2008; 68(5): 1601 - 1608.
[Abstract] [Full Text] [PDF]


Home page
J. Virol.Home page
N. Spardy, A. Duensing, D. Charles, N. Haines, T. Nakahara, P. F. Lambert, and S. Duensing
The Human Papillomavirus Type 16 E7 Oncoprotein Activates the Fanconi Anemia (FA) Pathway and Causes Accelerated Chromosomal Instability in FA Cells
J. Virol., December 1, 2007; 81(23): 13265 - 13270.
[Abstract] [Full Text] [PDF]


Home page
CarcinogenesisHome page
E. Barroso, R.L. Milne, L.P. Fernandez, P. Zamora, J.I. Arias, J. Benitez, and G. Ribas
FANCD2 associated with sporadic breast cancer risk
Carcinogenesis, September 1, 2006; 27(9): 1930 - 1937.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
T. Taniguchi and A. D. D'Andrea
Molecular pathogenesis of Fanconi anemia: recent progress
Blood, June 1, 2006; 107(11): 4223 - 4233.
[Abstract] [Full Text] [PDF]


Home page
Genes Dev.Home page
R. D. Kennedy and A. D. D'Andrea
The Fanconi Anemia/BRCA pathway: new faces in the crowd
Genes & Dev., December 15, 2005; 19(24): 2925 - 2940.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2005 by the American Association for Cancer Research.